These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15992072)

  • 1. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial.
    MacGowan AP
    Expert Opin Investig Drugs; 1999 Feb; 8(2):181-99. PubMed ID: 15992072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin: a new fluoroquinolone.
    Blondeau JM
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1877-95. PubMed ID: 11060784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
    MacGowan AP; Bowker KE; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [National Multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens].
    Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10878536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertapenem: a new carbapenem.
    Odenholt I
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
    Pucci MJ; Cheng J; Podos SD; Thoma CL; Thanassi JA; Buechter DD; Mushtaq G; Vigliotti GA; Bradbury BJ; Deshpande M
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1259-67. PubMed ID: 17242152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.